A PHASE II STUDY OF CHEMOTHERAPY, MOZOBIL AND G-CSF AS MOBILIZING THERAPY FOR DOUBLE AUTOLOGOUS TRANSPLANTATION (ASCT) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL NON HODGKIN LYMPHOMA (DLBCL), PET POSITIVE AFTER TWO R-DHAP Studio di fase II per valutare l'efficacia e la sicurezza di chemioterapia, mozobil e G-CSF come terapia mobilizzante per doppio trapianto autologo (ASCT) in pazienti affetti da Linfoma Non Hodgkin diffuso a grandi cellule B (DLBCL) recidivato o refrattario, PET positivo dopo 2 cicli R-DHAP

Trial Profile

A PHASE II STUDY OF CHEMOTHERAPY, MOZOBIL AND G-CSF AS MOBILIZING THERAPY FOR DOUBLE AUTOLOGOUS TRANSPLANTATION (ASCT) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL NON HODGKIN LYMPHOMA (DLBCL), PET POSITIVE AFTER TWO R-DHAP Studio di fase II per valutare l'efficacia e la sicurezza di chemioterapia, mozobil e G-CSF come terapia mobilizzante per doppio trapianto autologo (ASCT) in pazienti affetti da Linfoma Non Hodgkin diffuso a grandi cellule B (DLBCL) recidivato o refrattario, PET positivo dopo 2 cicli R-DHAP

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2014

At a glance

  • Drugs Plerixafor (Primary)
  • Indications Stem cell mobilisation
  • Focus Therapeutic Use
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 10 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top